🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Primary Mediastinal Diffuse Large B-cell Lymphoma

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites📍 Minneapolis📍 Columbus📍 Richmond Yazeed Sawalha · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site📍 Columbus Nathan Denlinger · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine Pembro Plus CAR T-cell Therapy in R/R in PMBCL NCT05934448Phase 22 sites📍 Boston📍 New York Jennifer Crombie, MD · Tests: Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) NCT07750886n/a1 site📍 Austin Natera, Inc. A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma NCT07788118Phase 1, Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: 7×19-THEMIS CAR-T cells Immunotherapy in Lymphoma NCT06796517n/a2 sites📍 Seoul📍 Seoul Sung-Soo Park · Tests: CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL NCT06742502Phase 22 sites📍 Fuzhou📍 Guangzhou Sun Yat-sen University · Tests: Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone) A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma NCT06486051Phase 23 sites📍 Auckland📍 Christchurch📍 Newtown Malaghan Institute of Medical Research · Tests: Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma NCT07097363Phase 21 site📍 Seattle University of Washington · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07365306Phase 23 sites📍 Duarte📍 Newnan📍 Zion City of Hope Medical Center · Tests: Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, B… A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies NCT06703892Phase 11 site📍 Taipei GenomeFrontier Therapeutics TW Co., Ltd. · Tests: GF-CART01, GF-CART01, GF-CART01 Italian Observational Study on CAR-T Therapy for Lymphoma NCT06339255n/a1 site📍 Milan Paolo Corradini Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients NCT07473167Phase 1, Phase 21 site📍 Seoul TICAROS Co., Ltd. · Tests: TC011 Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167n/a1 site📍 Portland OHSU Knight Cancer Institute · Tests: Non-Interventional Study Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05633615Phase 295 sites📍 Tucson📍 Tucson📍 Fayetteville SWOG Cancer Research Network · Tests: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Bio-CAR-T BS Study NCT05366569n/a1 site📍 Brescia Azienda Socio Sanitaria Territoriale degli Spedali Civili d… Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT05672251Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019Phase 136 sites📍 Gilbert📍 Newark📍 Pompano Beach Schrödinger, Inc. · Tests: SGR-1505 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites📍 Cleveland📍 Cleveland Paolo Caimi, MD · Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site📍 Boston Marcela V. Maus, M.D.,Ph.D. · Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL NCT02393157Phase 21 site📍 Valhalla New York Medical College · Tests: Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735Phase 17 sites📍 Calgary📍 Calgary📍 Vancouver British Columbia Cancer Agency · Tests: CLIC-2201 Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy NCT05377307n/a5 sites📍 Kaohsiung📍 Taipei📍 Taipei Pell Bio-Med Technology Co., Ltd. · Tests: Pell's lentiviral-based gene-edited immune cell therapy Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL NCT06500273Phase 286 sites📍 Gilbert📍 Hot Springs📍 Berkeley Allogene Therapeutics · Tests: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU NCT06116110n/a11 sites📍 Gilbert📍 Stanford📍 New Haven Miltenyi Biomedicine GmbH · Tests: Long-term Follow-Up Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients NCT04836507Phase 1, Phase 22 sites📍 Seoul📍 Seoul Curocell Inc. · Tests: CRC01, Fludarabine, Cyclophosphamide Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy NCT06238648Phase 26 sites📍 Rochester📍 St Louis📍 Hackensack Academic and Community Cancer Research United · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy